Remdesivir alleviates inflammation and tissue damage in experimental colitis via AnxA5 Signaling
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2025.116029 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Hailong Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, China. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Colitis, Alanine, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Science and Technology Planning Project of Shenzen Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Remdesivir, a broad-spectrum antiviral prodrug, has been investigated for its potential effects on inflammatory bowel disease (IBD). Using a mouse model with acute colitis induced by 3 % dextran sulfate sodium (DSS), we administered remdesivir at doses of 12.5 and 25 mg/kg from day 1 to 7. Our research demonstrated that remdesivir treatment notably decreased disease activity scores and improved colon tissue damage under the microscope. It also boosted the levels of tight junction proteins such as occludin and claudin-1, while reducing the production of inflammatory cytokines like Il-1β, Il-6, and Tnf-α, as well as the adhesion molecule Icam-1. Further analysis showed that remdesivir significantly reduced the expression of inflammatory markers CD3, EMR, and MPO in the mice's colorectal tissues. Additionally, it was found to regulate the gut microbiota and restore bile acid levels. Remdesivir was also observed to stabilize AnxA5, modulating the NF-κB pathway and thereby reducing inflammation, which was confirmed by its ability to counteract the effects of Si-AnxA5 suppression in LPS-treated Caco-2 cells. These findings indicate that remdesivir may activate the AnxA5 signaling pathway, offering a new perspective for treating experimental colitis. This suggests that remdesivir could be a valuable candidate for further development and therapeutic refinement in the context of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, China.
- The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, China. Electronic address: guxiaoting@nankai.edu.cn.
- Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin, China. Electronic address: cao…
- The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, China. Electronic address: honggang.zhou@nankai.edu.cn.
- The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, China; Nankai International Advanced Research Institute(Shenzhen Futian), She…
Förderung
- Science and Technology Planning Project of Shenzen Municipality
- National Natural Science Foundation of China
Zitieren
APA
Li, H., Yang, Y., Li, J., Hu, Y., Mao, R., Ye, X., Wu, X., Li, Z., Han, L., Gu, X., Cao, H., Zhou, H., & Yang, C. (2026). Remdesivir alleviates inflammation and tissue damage in experimental colitis via AnxA5 Signaling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.116029
Vancouver
Li H, Yang Y, Li J, Hu Y, Mao R, Ye X, et al. Remdesivir alleviates inflammation and tissue damage in experimental colitis via AnxA5 Signaling. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.116029
BibTeX
@article{Li2026,
author = {Li, Hailong and Yang, Ying and Li, Jinhe and Hu, Yayue and Mao, Ruiqi and Ye, Xiaoman and Wu, Xi and Li, Zherui and Han, Liqing and Gu, Xiaoting and Cao, Hailong and Zhou, Honggang and Yang, Cheng},
title = {Remdesivir alleviates inflammation and tissue damage in experimental colitis via AnxA5 Signaling},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2025.116029}
}
EUVIMED